Opinion|Videos|February 19, 2025
Emerging Immunotherapies in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how PD-L1 inhibitors such as durvalumab and sasanlimab represent a promising frontier in non–muscle-invasive bladder cancer (NMIBC) treatment. These immunotherapies work by unleashing the body’s immune response against cancer cells, potentially offering new options for patients whose disease doesn’t respond to conventional therapies such as BCG. Their ongoing phase 3 trials could establish immunotherapy as a valuable addition to the NMIBC treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss PD-L1 inhibitors durvalumab and sasanlimab, which are currently in phase 3 trials for NMIBC. How do you see immunotherapies contributing to the treatment of NMIBC?
Advertisement
Related to this article
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A decision is expected by the fourth quarter of 2026.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Advertisement
Advertisement
Trending on Urology Times
1
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
2
One year of Inlexzo: Evolving care in BCG-unresponsive NMIBC
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
PSMA PET Radiotracers and Access Barriers in Prostate Cancer
5